1 University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Austria.
2 University Clinic of Radiology, Medical University of Innsbruck, Austria.
Eur Heart J Acute Cardiovasc Care. 2017 Oct;6(7):640-649. doi: 10.1177/2048872616661691. Epub 2016 Jul 20.
In patients with acute ST-elevation myocardial infarction (STEMI), elevated concentrations of inflammatory markers are correlated with worse clinical outcome. The aim of this study was comprehensively to investigate the relationship of circulating markers of inflammation with myocardial and microvascular damage after STEMI.
In 111 consecutive STEMI patients, blood samples were obtained on admission and from day 1 to day 4 after primary percutaneous coronary intervention and analysed for high-sensitivity C-reactive protein (hs-CRP), white blood cell count and fibrinogen. Cardiac magnetic resonance imaging was performed within the first week and 4 months after primary percutaneous coronary intervention.
Peak concentrations of hs-CRP (20.5 (9.6-44.4) mg/L), white blood cell count (12.4 (10.5-15.3) G/L) and fibrinogen (3640 (3150-4550) mg/L) showed significant correlations with both infarct size ( r=0.31 to 0.41; P<0.01) and left ventricular ejection fraction ( r=-0.29 to -0.39; P<0.01) assessed in the acute as well as chronic stage following STEMI. Furthermore, peak concentrations of these inflammatory markers were significantly higher in patients with microvascular obstruction compared to patients without microvascular obstruction ( P⩽0.01). C-statistics revealed that the prognostic values of all three biomarkers for the prediction of large chronic infarct size (>8% of left ventricular myocardial mass) were moderate without significant differences (area under the curve: hs-CRP 0.73 (95% confidence interval (CI) 0.63-0.82), white blood cell count 0.67 (95% CI 0.56-0.78) and fibrinogen 0.69 (95% CI 0.59-0.79); all P>0.12). Combination of inflammatory markers did not significantly increase the area under the curve ( P>0.05).
In reperfused STEMI patients, increased levels of hs-CRP, white blood cell count and fibrinogen are associated with decreased left ventricular function and more pronounced myocardial damage at baseline and 4 months after infarction.
在急性 ST 段抬高型心肌梗死(STEMI)患者中,炎症标志物浓度升高与临床预后较差相关。本研究旨在全面探讨炎症循环标志物与 STEMI 后心肌和微血管损伤的关系。
在 111 例连续的 STEMI 患者中,在首次经皮冠状动脉介入治疗(pPCI)前和 pPCI 后第 1 天至第 4 天采集血样,并分析高敏 C 反应蛋白(hs-CRP)、白细胞计数和纤维蛋白原。在 pPCI 后第 1 周和第 4 个月行心脏磁共振成像检查。
hs-CRP(20.5(9.6-44.4)mg/L)、白细胞计数(12.4(10.5-15.3)G/L)和纤维蛋白原(3640(3150-4550)mg/L)的峰值浓度与梗死面积(r=0.31 至 0.41;P<0.01)和 STEMI 后急性期和慢性期的左心室射血分数(r=-0.29 至-0.39;P<0.01)呈显著相关。与无微血管阻塞患者相比,有微血管阻塞的患者这些炎症标志物的峰值浓度显著更高(P⩽0.01)。C 统计量显示,三种生物标志物预测大面积慢性梗死面积(>8%左心室心肌质量)的预后价值相当,无显著差异(曲线下面积:hs-CRP 0.73(95%置信区间(CI)0.63-0.82),白细胞计数 0.67(95%CI 0.56-0.78)和纤维蛋白原 0.69(95%CI 0.59-0.79);均 P>0.12)。炎症标志物联合使用并未显著增加曲线下面积(P>0.05)。
在再灌注治疗的 STEMI 患者中,hs-CRP、白细胞计数和纤维蛋白原水平升高与基线和梗死 4 个月后左心室功能降低和更明显的心肌损伤相关。